glp-1 receptor agonist type 1 diabetes randomized trial New Developments in Pharmacological Treatment of Obesity and 2 Diabetes—Beyond and within Agonists Management of type 2 diabetes
Description
contributed to study design, data collection, raw data verification, data analysis, data interpretation, and drafting and revisions of the manuscript
Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease
[DOI] [PMC free article] [PubMed] [Google Scholar] 42.Joseph F
According to the Cleveland Clinic, the higher the dose of the GLP-1 agonist, the more extreme the effects
doi: 10.1016/j.cmet.2013.04.008 21 ChegeniMHayesAMRGonzalezTDManderfeldMMLimJMenonRSet al
The global prevalence of 537 million affected in the age group of 2079 years in 2021 will rise to 783 million in 2045, with the lowest increase in incidence in Europe (13%) and the highest in the African countries south of the Sahara (134%) (1)
